Cellular and T cell engager Immunotherapy
Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
Saad Z. Usmani, MD MBA
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York, United States